Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.

Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, Rainoldi JL, Szczepanski L, Ung KA, Kleczkowski D, Ahlbom H, Naesdal J, Hawkey C.

Am J Gastroenterol. 2006 Apr;101(4):701-10. Epub 2006 Feb 22.

PMID:
16494585
3.

Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors.

Hawkey C, Talley NJ, Yeomans ND, Jones R, Sung JJ, Långström G, Naesdal J, Scheiman JM; NASA1 SPACE1 Study Group.

Am J Gastroenterol. 2005 May;100(5):1028-36.

PMID:
15842575
4.

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.

Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, Rostom A, Symmons D.

Health Technol Assess. 2006 Oct;10(38):iii-iv, xi-xiii, 1-183. Review.

5.

Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients.

Sugano K, Kinoshita Y, Miwa H, Takeuchi T; Esomeprazole NSAID Preventive Study Group.

Aliment Pharmacol Ther. 2012 Jul;36(2):115-25. doi: 10.1111/j.1365-2036.2012.05133.x. Epub 2012 May 16.

6.
8.

Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers.

Morgner A, Miehlke S, Labenz J.

Expert Opin Pharmacother. 2007 May;8(7):975-88. Review.

PMID:
17472543
9.
10.

Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers.

Sostek MB, Fort JG, Estborn L, Vikman K.

Curr Med Res Opin. 2011 Apr;27(4):847-54. doi: 10.1185/03007995.2011.555756. Epub 2011 Feb 14.

PMID:
21319944
11.

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.

Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, Mann SG, Simon TJ, Sturrock RD, Russell RI.

N Engl J Med. 1996 May 30;334(22):1435-9.

12.

Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.

Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, Hui AJ, Leung VK, Lee VW, Lai LH, Wong GL, Chow DK, To KF, Leung WK, Chiu PW, Lee YT, Lau JY, Chan HL, Ng EK, Sung JJ.

Lancet. 2007 May 12;369(9573):1621-6.

PMID:
17499604
13.

Prevention of NSAID-induced gastroduodenal ulcers.

Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J.

Cochrane Database Syst Rev. 2002;(4):CD002296. Review.

PMID:
12519573
14.

Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.

Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK.

Am J Med. 2005 Nov;118(11):1271-8.

PMID:
16271912
15.

Prevention of NSAID-induced gastroduodenal ulcers.

Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J.

Cochrane Database Syst Rev. 2000;(4):CD002296. Review. Update in: Cochrane Database Syst Rev. 2002;(4):CD002296.

PMID:
11034748
16.

Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole.

Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, Huang B; NSAID-Associated Gastric Ulcer Prevention Study Group.

Arch Intern Med. 2002 Jan 28;162(2):169-75.

PMID:
11802750
17.

Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies.

Hawkey CJ, Talley NJ, Scheiman JM, Jones RH, Långström G, Naesdal J, Yeomans ND; NASA/SPACE author group.

Arthritis Res Ther. 2007;9(1):R17.

18.

Prevention of chronic NSAID induced upper gastrointestinal toxicity.

Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J.

Cochrane Database Syst Rev. 2000;(3):CD002296. Review. Update in: Cochrane Database Syst Rev. 2000;(4):CD002296.

PMID:
10908548
19.

Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs.

Sugano K, Kinoshita Y, Miwa H, Takeuchi T; Esomeprazole NSAID Preventive Study Group.

BMC Gastroenterol. 2013 Mar 26;13:54. doi: 10.1186/1471-230X-13-54.

20.

Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial.

Sugano K, Kontani T, Katsuo S, Takei Y, Sakaki N, Ashida K, Mizokami Y, Asaka M, Matsui S, Kanto T, Soen S, Takeuchi T, Hiraishi H, Hiramatsu N.

J Gastroenterol. 2012 May;47(5):540-52. doi: 10.1007/s00535-012-0541-z. Epub 2012 Mar 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk